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When almost 60 % of the world’s population is predicted
to be overweight by 2030 [1], dosing regimens that are
developed and tested in non-obese patients will be in-
appropriate for the future use of drugs. Specifically,
should we no longer accept the “one-size-fits-all” men-
tality of antibiotic dosing and accept that individuals
may in fact need to be dosed… individually? Almost all
clinicians use antibiotics daily. Most use guidelines as
dosing rules rather than a guide. Particularly in critical
illness where dramatic changes in antibiotic concentra-
tions can occur with similar doses, accepting guidelines
as dosing rules is likely to be flawed [2].
Antibiotic pharmacokinetics are different in the critically
ill compared with other patient groups [3]. Firstly, there
are changes to the volume of distribution (Vd). Particularly
in patients with sepsis, fluid shifts from the intravascular
space to the interstitium lowers the intravascular concen-
trations of hydrophilic antimicrobials [4]. Furthermore,
given a decrease in plasma albumin concentration is seen
in approximately 40 % of the critically ill, antimicrobials
may further extravasate, additionally increasing Vd.
Furthermore, drug clearance may be altered in those
with renal impairment (hydrophilic drugs) or hepatic
impairment (largely lipophilic drugs). Moreover, there
is increasing evidence of enhanced renal elimination of
renally cleared drugs (augmented renal clearance) in
the critically ill [5].
In the obese, there can be a significant change in the
Vd of both hydrophilic and lipophilic antimicrobials
consequential to increases in both adipose and lean
muscle mass. The degree to which Vd is altered is gener-
ally regarded to be a function of the lipophillicity of the
drug, although hydrophilic antimicrobials also have Vd
alterations secondary to an increased volume of lean
muscle, the significance of which is debated [6].
Additionally, the precise effect obesity has on antimicro-
bial clearance is unclear, with literature scarce. In healthy
obese patients renal flow is augmented compared with
non-obese [7]. The exact mechanism is debated, though
“obesity-related glomerulopathy”, a collective term for
glomerulomegaly, with or without focal segmental glo-
merulosclerosis, along with increased renal plasma flow
and associated increased glomerular filtration rate is likely
to be the cause [8]. As patients age and obesity-related
nephropathies develop, however, renal function can be
reduced [9]. Subsequently, obese patients may develop
reduced drug clearance compared with age-matched
comparators, especially those critically ill with augmented
renal clearance.
The abovementioned changes to both Vd and clear-
ance become especially important in those patients that
are “super obese”. Significantly higher loading doses are
likely to be necessary to accommodate the increased Vd,
whilst comparatively lower maintenance doses may be
required to avoid drug toxicities in those with reduced
clearance. Clearly, when combining the effects of being
critically ill and obese, it is difficult to accurately predict
the pharmacokinetics of any given antimicrobial. Ultim-
ately, the assumption of linear correlations between lean
or total body weight, Vd and drug clearance is problem-
atic and prospective pharmacokinetic trials in critically
ill obese patients should be performed to define robust
dosing guidelines.
Vancomycin is a glycopeptide antibiotic whose clinical
response is dependent on the 24-h area-under-the-con-
centration-time curve (AUC) to minimum inhibitory
concentration (MIC) ratio. It is generally accepted that a
target AUC:MIC ratio >400 is optimal [10]. Despite being
hydrophilic, vancomycin has a wide Vd in critically ill pa-
tients (>1.0 L/kg) and >90 % is renally cleared. As such,
taking into account the abovementioned pharmacokinetic
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alterations in both the obese and the critically ill, dosing
can be challenging.
Recent literature comparing vancomycin dosing require-
ments administered by continuous infusion in obese versus
non-obese patients has presented two interesting findings.
Firstly, the daily weight-based vancomycin dose was signifi-
cantly lower for obese compared with non-obese patients
when administered by continuous infusion whilst achieving
target concentrations [11]. This is unsurprising given
clearance is the primary determinant of maintaining
steady state concentrations after initial loading is complete
[12]. Furthermore, no significant difference in non-weight
normalized vancomycin clearance between obese and
non-obese patients with preserved renal function was
found with minimal correlation to total body weight [11].
This implies that measures of renal function rather than
measures of weight are most important for maintenance
dosing. These data are similar to recent findings in
non-obese critically ill populations [12], although there
are ultimately many ill-defined variables that preclude
direct extrapolation of non-obese data.
Ultimately, the paucity of data in obese, critically ill
populations may force us to accept that therapeutic drug
monitoring (TDM) is still the way forward. There is,
however, a caveat: the AUC:MIC ratio is rarely measured
in clinical practice. Rather, serum trough concentration
targets of 15–20 mg/L are advocated as a reliable surrogate.
Neely et al. [13] recently showed, however, that the AUC
was underestimated by an average of 23 % when using
trough concentrations alone, leading to potential excessive
vancomycin exposure and unnecessary risks of toxicity. As
such, caution when relying on this alone is prudent.
Whilst vancomycin concentrations are easily mea-
sured, concentrations of other antibiotics used in obese
patients are measured far less frequently. For example, a
recent review [14] concluded that very few hospitals
worldwide perform beta-lactam TDM on a routine basis
despite its availability likely being much higher [15]. This
disparity may be because, traditionally, beta-lactam
antibiotics had a wide therapeutic window and risk of
toxicity was low (compared with other antibiotics rou-
tinely measured). However, given the effectiveness of beta-
lactam antibiotics depends on the duration that serum
concentrations are greater than the target pathogen’s MIC
and there is increasing evidence of beta-lactam resistance,
it is easy to see that we may inadvertently dose patients
poorly if assumptions of uniform pharmacokinetics be-
tween non-obese and obese populations are made.
In conclusion, vancomycin clearance may be similar in
obese and non-obese populations, with smaller weight-
based dosages required to maintain steady state concentra-
tions. Despite this, given the relative paucity of prospective
data surrounding antibiotic pharmacokinetics in the com-
bined obese and critically ill cohort, it is clear that TDM
makes sense to ensure target concentrations are achieved
to increase the likelihood of clinical efficacy.
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